172 related articles for article (PubMed ID: 27701875)
21. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
Albany C; Brames MJ; Fausel C; Johnson CS; Picus J; Einhorn LH
J Clin Oncol; 2012 Nov; 30(32):3998-4003. PubMed ID: 22915652
[TBL] [Abstract][Full Text] [Related]
22. 2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting.
Ruhlmann CH; Jahn F; Jordan K; Dennis K; Maranzano E; Molassiotis A; Roila F; Feyer P
Support Care Cancer; 2017 Jan; 25(1):309-316. PubMed ID: 27624464
[TBL] [Abstract][Full Text] [Related]
23. Prevention and management of chemotherapy-induced nausea and vomiting.
Moradian S; Howell D
Int J Palliat Nurs; 2015 May; 21(5):216, 218-24. PubMed ID: 26107543
[TBL] [Abstract][Full Text] [Related]
24. Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
Hargreaves R; Ferreira JC; Hughes D; Brands J; Hale J; Mattson B; Mills S
Ann N Y Acad Sci; 2011 Mar; 1222():40-8. PubMed ID: 21434941
[TBL] [Abstract][Full Text] [Related]
25. Nausea and vomiting induced by gastrointestinal radiation therapy: current status and future directions.
Dennis K; Poon M; Chow E
Curr Opin Support Palliat Care; 2015 Jun; 9(2):182-8. PubMed ID: 25872120
[TBL] [Abstract][Full Text] [Related]
26. Aprepitant--where do we stand in the control of chemotherapy-induced nausea and vomiting?
Sarcev T; Secen N; Zaric B; Milovancev A
J BUON; 2008; 13(3):333-9. PubMed ID: 18979546
[TBL] [Abstract][Full Text] [Related]
27. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
[TBL] [Abstract][Full Text] [Related]
28. Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy.
Molassiotis A; Nguyen AM; Rittenberg CN; Makalinao A; Carides A
Future Oncol; 2013 Oct; 9(10):1443-50. PubMed ID: 23987791
[TBL] [Abstract][Full Text] [Related]
29. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Carides G; Elmer M; Schmidt C; Evans JK; Horgan KJ
J Clin Oncol; 2003 Nov; 21(22):4105-11. PubMed ID: 14559891
[TBL] [Abstract][Full Text] [Related]
30. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
31. Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey.
Vidall C; Fernández-Ortega P; Cortinovis D; Jahn P; Amlani B; Scotté F
Support Care Cancer; 2015 Nov; 23(11):3297-305. PubMed ID: 25953380
[TBL] [Abstract][Full Text] [Related]
32. Gastroparesis-associated refractory nausea treated with aprepitant.
Fahler J; Wall GC; Leman BI
Ann Pharmacother; 2012 Dec; 46(12):e38. PubMed ID: 23191934
[TBL] [Abstract][Full Text] [Related]
33. Optimising antiemetic therapy: what are the problems and how can they be overcome?
Aapro M
Curr Med Res Opin; 2005 Jun; 21(6):885-97. PubMed ID: 15969889
[TBL] [Abstract][Full Text] [Related]
34. [Comparative study of an antiemetic NK1 receptor-antagonist in lung cancer patients treated with divided doses for Cisplatin].
Sato H; Wada K; Umehara K; Otsu K; Wakamoto A; Hatsuyama T; Fujita A; Sekine K
Gan To Kagaku Ryoho; 2013 Jun; 40(6):733-6. PubMed ID: 23863648
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of aprepitant among patients aged 65 and over receiving moderately to highly emetogenic chemotherapy: a meta-analysis of unpublished data from previously published studies.
Chapell R; Aapro MS
J Geriatr Oncol; 2013 Jan; 4(1):78-83. PubMed ID: 24071495
[TBL] [Abstract][Full Text] [Related]
36. Addition of Aprepitant (Emend®) to Standard Antiemetic Regimen Continued for 7 Days after Chemotherapy for Stem Cell Transplantation Provides Significant Reduction of Vomiting.
Svanberg A; Birgegård G
Oncology; 2015; 89(1):31-6. PubMed ID: 25659986
[TBL] [Abstract][Full Text] [Related]
37. Prophylaxis versus treatment: is there a better way to manage radiotherapy-induced nausea and vomiting?
Horiot JC
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1018-25. PubMed ID: 15519770
[TBL] [Abstract][Full Text] [Related]
38. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
Gralla RJ; de Wit R; Herrstedt J; Carides AD; Ianus J; Guoguang-Ma J; Evans JK; Horgan KJ
Cancer; 2005 Aug; 104(4):864-8. PubMed ID: 15973669
[TBL] [Abstract][Full Text] [Related]
39. Aprepitant vs. multimodal prophylaxis in the prevention of nausea and vomiting following extended-release epidural morphine.
Hartrick CT; Tang YS; Hunstad D; Pappas J; Muir K; Pestano C; Silvasi D
Pain Pract; 2010; 10(3):245-8. PubMed ID: 20230453
[TBL] [Abstract][Full Text] [Related]
40. Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines.
Feyer PCh; Maranzano E; Molassiotis A; Clark-Snow RA; Roila F; Warr D; Olver I
Support Care Cancer; 2005 Feb; 13(2):122-8. PubMed ID: 15592688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
